FDA Approves First Oral GLP 1 Weight Loss Pill With Up to 17% Average Weight Reduction

The US Food and Drug Administration (FDA) has approved the first oral GLP 1 medication for chronic weight management, marking a significant milestone in obesity treatment. Developed by Novo Nordisk, the daily Wegovy pill offers patients an alternative to injectable therapies while delivering clinically meaningful weight loss. Supported by late stage clinical trial data, the approval expands access to GLP 1 treatment for adults living with obesity or overweight conditions and aligns with growing interest in therapies that address both weight and heart related risks.

Up to 17% Average Weight Loss Seen in Phase 3 Trial

The FDA approval is based on results from the Phase 3 OASIS 4 clinical trial, which evaluated the safety and effectiveness of oral semaglutide in adults with obesity or overweight without diabetes. Participants received either the Wegovy pill or a placebo alongside lifestyle interventions, including reduced calorie intake and increased physical activity.

After 64 weeks of treatment, patients who adhered to the assigned therapy achieved an average weight loss of 17%, compared with around 3% in the placebo group. This analysis reflects outcomes among participants who stayed on treatment and followed the study protocol.

Researchers also examined outcomes using a broader statistical approach that included all participants, regardless of treatment discontinuation or adherence. Under this analysis, average weight loss reached approximately 14%, while those receiving placebo experienced about 2% weight loss. These findings highlight that the oral formulation delivers consistent and clinically meaningful results, even when real world treatment patterns are taken into account.

Together, the trial results place oral semaglutide among the most effective weight management therapies currently approved, with efficacy comparable to injectable GLP 1 options.

Once Daily Oral Wegovy Expands Access Beyond Injections

The newly approved Wegovy tablet contains 25 mg of oral semaglutide and is taken once daily. Until now, GLP 1 receptor agonists approved for chronic weight management required weekly injections, which some patients found difficult or uncomfortable.

By offering an oral option, the FDA approval addresses a long standing barrier to treatment adoption. Many patients prefer pills over injections, particularly for long term therapies. As a result, the oral Wegovy pill may help broaden access to GLP 1 treatment among individuals who previously hesitated to start injectable medications.

However, the FDA emphasized that medication alone is not sufficient. Patients must use the oral Wegovy pill in combination with a reduced calorie diet and increased physical activity. The approved indication applies to adults with obesity, defined by body mass index criteria, as well as adults who are overweight and have at least one weight related health condition such as hypertension or dyslipidemia.

This approval reflects a broader shift toward more patient centered approaches in obesity care, where convenience and treatment preferences play a growing role. Novo Nordisk expects to begin the initial rollout in the United States in early 2026, with availability in other regions subject to regulatory review and approval by local health authorities.

Proven Cardiovascular Risk Reduction and Known Safety Profile

In addition to its weight loss indication, the FDA also approved the oral Wegovy pill to reduce the risk of major adverse cardiovascular events. These events include heart attack, stroke, and cardiovascular death in adults with overweight or obesity who already have established cardiovascular disease.

This expanded indication builds on existing evidence for semaglutide, which has previously shown cardiovascular benefits in high risk populations. For patients living with both obesity and heart disease, the approval reinforces the role of GLP 1 therapy as part of a broader risk reduction strategy.

Safety findings from the OASIS 4 trial were consistent with the known profile of semaglutide. The most commonly reported side effects included nausea, vomiting, and diarrhea. These gastrointestinal symptoms occurred most often during early treatment or dose escalation and were generally mild to moderate in severity.

No new safety signals emerged during the trial, supporting the overall tolerability of the oral formulation. As with other GLP 1 therapies, clinicians are expected to follow established dosing and monitoring guidelines.

Author

[email protected]